They used two breast cancer cell lines, MDA-MB-231 cells (ER−) and MCF-7 (ER+), and the non-neoplastic cell line MCF10A, and showed that PJ, or a combination of its components, luteolin plus ellagic acid plus punicic acid, increased cancer cell adhesion, decreased cancer cell migration, and reduced growth of the breast cancer cells, without affecting the normal cells. The gene discussed is ESR1; the disease is breast cancer.